The Neuroprotective Effect of Short-chain Fatty Acids Against Hypoxia-reperfusion Injury DOI Creative Commons

Anjit K. Harijan,

Retnamony Kalaiarasan,

Amit Ghosh

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Dec. 23, 2023

Abstract Gut microbe-derived short-chain fatty acids (SCFAs) are known to have a profound impact on various brain functions, including cognition, mood, and overall neurological health. However, their role, if any, in protecting against hypoxic injury ischemic stroke has not been extensively studied. In this study, we investigated the effects of two major SCFAs abundant gut, propionate (P) butyrate (B), hypoxia-reperfusion using neuronal cell line zebrafish model. Neuro 2a (N2a) cells treated with P B exhibited reduced levels mitochondrial cytosolic reactive oxygen species (ROS), diminished loss membrane potential, suppressed caspase activation, lower rates death when exposed CoCl 2 -induced hypoxia, compared control group. Furthermore, adult fed SCFAs-supplemented feeds showed less susceptibility conditions group, as indicated by multiple behavioral measures. Histological analysis TTC-stained sections revealed lesser damage SCFAs-fed We also found that FABP7 (also BLBP), neuroprotective acid binding protein, was upregulated brains Additionally, overexpressed N2a cells, it protected from injury. Overall, our data clearly demonstrates role suggests potential dietary supplementation mitigate stroke-induced damage. Highlights Short-chain (SCFA) Propionate Butyrate (B) protect hypoxia-reperfusion. Zebrafish, an SCFA-supplemented diet, more resilient diet boost expression (fatty protein). overexpression provides protection reduce (ROS) increase FABP7, contributing neuroprotection.

Language: Английский

Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies DOI Creative Commons
Xuxiang Zhang, Beisha Tang, Jifeng Guo

et al.

Translational Neurodegeneration, Journal Year: 2023, Volume and Issue: 12(1)

Published: Dec. 15, 2023

Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases. The typical symptomatology PD includes motor symptoms; however, a range nonmotor symptoms, such as intestinal issues, usually occur before symptoms. Various microorganisms inhabiting gastrointestinal tract can profoundly influence physiopathology central nervous system through neurological, endocrine, and immune pathways involved in microbiota-gut-brain axis. In addition, extensive evidence suggests that gut microbiota strongly associated with PD. This review summarizes latest findings on microbial changes their clinical relevance, describes underlying mechanisms which bacteria may mediate PD, discusses correlations between microbes anti-PD drugs. this outlines status research therapies for future directions PD-gut research.

Language: Английский

Citations

45
Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications DOI Creative Commons
Balaraman Kalyanaraman, Gang Cheng, Micaël Hardy

et al.

Redox Biology, Journal Year: 2024, Volume and Issue: 71, P. 103092 - 103092

Published: Feb. 16, 2024

In this review, we explore how short-chain fatty acids (SCFAs) produced by the gut microbiome affect Parkinson's disease (PD) through their modulatory interactions with alpha-synuclein, neuroinflammation, and oxidative stress mediated reactive oxygen nitrogen species (ROS/RNS). particular, SCFAs-such as acetate, propionate, butyrate-are involved in gut-brain communication can modulate alpha-synuclein aggregation, a hallmark of PD. The patients PD has lower levels SCFAs than healthy individuals. Probiotics may be potential strategy to restore alleviate symptoms, but underlying mechanisms are not fully understood. Also discuss present guts brains PD, induce neuroinflammation via ROS/RNS. Alpha-synuclein is considered an early biomarker for link axis pathogenesis. Therefore, elucidating role impact on alpha-synuclein-induced microglia ROS/RNS crucial pathogenesis treatment.

Language: Английский

Citations

30
The Inflammatory Mechanism of Parkinson’s Disease: Gut Microbiota Metabolites Affect the Development of the Disease Through the Gut–Brain Axis DOI Creative Commons
Ai Gao, Jiaqi Lv, Yanwei Su

et al.

Brain Sciences, Journal Year: 2025, Volume and Issue: 15(2), P. 159 - 159

Published: Feb. 6, 2025

Parkinson's disease is recognized as the second most prevalent neurodegenerative disorder globally, with its incidence rate projected to increase alongside ongoing population growth. However, precise etiology of remains elusive. This article explores inflammatory mechanisms linking gut microbiota disease, emphasizing alterations in and their metabolites that influence disease's progression through bidirectional transmission signals along gut-brain axis. Building on this mechanistic framework, further discusses research methodologies treatment strategies focused metabolites, including metabolomics detection techniques, animal model investigations, therapeutic approaches such dietary interventions, probiotic treatments, fecal transplantation. Ultimately, aims elucidate relationship between underlying thereby paving way for novel avenues condition.

Language: Английский

Citations

1
The role of HLA-DR on plasmacytoid dendritic cells in mediating the effects of Butyrivibrio gut microbiota on Parkinson’s disease DOI
Zihao Wang, Huan Xia,

Tingting Feng

et al.

Neurological Sciences, Journal Year: 2024, Volume and Issue: 45(8), P. 3809 - 3815

Published: March 19, 2024

Language: Английский

Citations

4
The Interaction Between Nutraceuticals and Gut Microbiota: a Novel Therapeutic Approach to Prevent and Treatment Parkinson’s Disease DOI

Liyan Yao,

Yong Yang,

Xiaowei Yang

et al.

Molecular Neurobiology, Journal Year: 2024, Volume and Issue: 61(11), P. 9078 - 9109

Published: April 8, 2024

Language: Английский

Citations

4
Short-Chain Fatty Acid Aggregates Alpha-Synuclein Accumulation and Neuroinflammation via GPR43-NLRP3 Signaling Pathway in a Model Parkinson’s Disease DOI

Yi Qu,

Ke An, Danlei Wang

et al.

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 4, 2025

Language: Английский

Citations

0
Plasma Metabolites as Mediators Between Gut Microbiota and Parkinson’s Disease: Insights from Mendelian Randomization DOI

Jianzhun Chen,

Liuhui Zhu,

Fang Wang

et al.

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Language: Английский

Citations

0
Short-chain fatty acids in Huntington's disease: Mechanisms of action and their therapeutic implications DOI
Mohamed J. Saadh,

Hanan Hassan Ahmed,

Radhwan Abdul Kareem

et al.

Pharmacology Biochemistry and Behavior, Journal Year: 2025, Volume and Issue: unknown, P. 173972 - 173972

Published: Feb. 1, 2025

Language: Английский

Citations

0
Comparative analysis of Parkinson’s and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion DOI Creative Commons

Maeve E. Krueger,

Jake Boles, Zachary D. Simon

et al.

npj Parkinson s Disease, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 19, 2025

Abstract Epidemiological studies reveal that inflammatory bowel disease (IBD) is associated with an increased risk of Parkinson’s (PD). Gut dysbiosis has been documented in both PD and IBD, however it currently unknown whether gut underlies the epidemiological association between diseases. To identify shared distinct features IBD microbiome, we recruited 54 PD, 26 16 healthy control individuals performed first joint analysis metagenomes. Larger, publicly available metagenomic datasets were also analyzed to validate extend our findings. Depletions short-chain fatty acid (SCFA)-producing bacteria, including Roseburia intestinalis, Faecalibacterium prausnitzii, Anaerostipes hadrus , Eubacterium rectale as well depletion SCFA-synthesis pathways detected across datasets, suggesting these microbes may influence for development.

Language: Английский

Citations

0
Role of Antioxidants in Modulating the Microbiota–Gut–Brain Axis and Their Impact on Neurodegenerative Diseases DOI Open Access
Natalia Kurhaluk, Piotr Kamiński, Rafał Bilski

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3658 - 3658

Published: April 12, 2025

This narrative review presents the role of antioxidants in regulating gut microbiota and impact on gut–brain axis, with a particular focus neurodegenerative diseases, such as Alzheimer’s (AD) Parkinson’s disease (PD). These diseases are characterised by cognitive decline, motor dysfunction, neuroinflammation, all which significantly exacerbated oxidative stress. elucidates contribution damage to progression explores potential mitigate these pathological processes through modulation associated pathways. Based recent studies retrieved from reputable databases, including PubMed, Web Science, Scopus, this article outlines mechanisms influence health exert neuroprotective effects. Specifically, it discusses how antioxidants, polyphenols, vitamins, flavonoids, contribute reduction reactive oxygen species (ROS) production thereby promoting neuronal survival minimising brain. In addition, modulating key molecular pathways involved stress NF-κB, Nrf2, MAPK, PI3K/AKT pathways, regulate ROS generation, inflammatory cytokine expression, antioxidant responses essential for maintaining cellular homeostasis both central nervous system. complex relationship between gut-derived metabolites, stress, highlighting dysbiosis—an imbalance microbiota—can exacerbate accelerating AD PD. The also examines short-chain fatty acids (SCFAs) produced beneficial bacteria attenuate neuroinflammation damage. Furthermore, therapeutic microbiota-targeted interventions, delivery probiotics prebiotics, innovative strategies restore microbial support brain health. By synthesising current knowledge interplay underlying neurodegeneration, highlights promise antioxidant-based interventions mitigating progression. It need further research into antioxidant-rich dietary microbiota-focused therapies promising avenues prevention treatment diseases.

Language: Английский

Citations

0